Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Cash from Restructuring (2024 - 2025)

Lyra Therapeutics (LYRA) has disclosed Cash from Restructuring for 2 consecutive years, with -$427000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Restructuring fell 124.71% to -$427000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$1.8 million, a N/A change, with the full-year FY2024 number at $4.3 million, changed N/A from a year prior.
  • Cash from Restructuring was -$427000.0 for Q3 2025 at Lyra Therapeutics, up from -$553000.0 in the prior quarter.
  • In the past five years, Cash from Restructuring ranged from a high of $1.7 million in Q3 2024 to a low of -$553000.0 in Q2 2025.